Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar - Scorecard - MDSpire

Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar

  • By

  • Sana Bentebbal

  • Ahmed Zaqout

  • Bakhita Meqbel

  • Ilham Bensmail

  • Abdullah Aldushain

  • Alberto de la Fuente

  • Remy Thomas

  • Adviti Naik

  • Hibah Shaath

  • Neyla S. Al-Akl

  • Abdi Adam

  • Houda Y. A. Moussa

  • Kyung C. Shin

  • Rowaida Z. Taha

  • Mohammed Abukhattab

  • Muna A. Al-Maslamani

  • Nehad M. Alajez

  • Abdelilah Arredouani

  • Yongsoo Park

  • Sara A. Abdulla

  • Omar M. A. El-Agnaf

  • Houari B. Abdesselem

  • Ali S. Omrani

  • Julie Decock

  • April 24, 2026

  • 0 min

Share

Clinical Scorecard: Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar

At a Glance

CategoryDetail
ConditionCOVID-19
Key MechanismsAlterations in plasma proteome following BNT162b2 booster vaccination.
Target PopulationHealthy individuals, both infection-naïve and previously infected.
Care SettingPost-vaccination monitoring and research.

Key Highlights

  • Significant increase in PARP-1 and decrease in MMP-7 post-booster.
  • Proteomic changes observed up to 6 months after vaccination.
  • Dysregulation of inflammatory proteins noted in both infection-naïve and previously infected individuals.
  • Longitudinal profiling provides insights into immune readiness.
  • Findings may inform future vaccination strategies and resource allocation.

Guideline-Based Recommendations

Diagnosis

  • Monitor proteomic markers to assess immune response post-vaccination.

Management

  • Consider booster vaccination for high-risk populations to maintain immunity.

Monitoring & Follow-up

  • Evaluate plasma protein levels at 3 and 6 months post-booster.

Risks

  • Potential for ongoing viral transmission despite vaccination.

Patient & Prescribing Data

Healthy individuals, including those previously infected with SARS-CoV-2.

Booster vaccination may enhance immune response and alter inflammatory markers.

Clinical Best Practices

  • Utilize proteomic profiling to tailor vaccination strategies.
  • Monitor for long-term effects of vaccination on inflammatory markers.

References

Original Source(s)

Longitudinal Analysis of Plasma Proteomic Alterations After BNT162b2 COVID-19 Booster Vaccination in Qatar

  • by Sana Bentebbal, Ahmed Zaqout, Bakhita Meqbel, Ilham Bensmail, Abdullah Aldushain, Alberto de la Fuente, Remy Thomas, Adviti Naik, Hibah Shaath, Neyla S. Al-Akl, Abdi Adam, Houda Y. A. Moussa, Kyung C. Shin, Rowaida Z. Taha, Mohammed Abukhattab, Muna A. Al-Maslamani, Nehad M. Alajez, Abdelilah Arredouani, Yongsoo Park, Sara A. Abdulla, Omar M. A. El-Agnaf, Houari B. Abdesselem, Ali S. Omrani, Julie Decock

  • April 24, 2026

Related Content

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study

SARS-CoV-2 and reproductive system: a scientometric study

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing